ProDERM study results of Octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine

Investigators tested the use of intravenous immune globulin (IVIg) for the treatment of adults with dermatomyositis, and a significantly higher percentage of patients experienced at least minimal improvement in disease activity in comparison with placebo in the first-ever phase 3, international, multicenter, randomized, placebo-controlled trial of the human plasma derived therapy for the condition.

Until this trial, published October 6, 2021, in The New England Journal of Medicine, there had never been an extensive evaluation of IVIg for the treatment of dermatomyositis, the study’s authors note. The study provided efficacy data for Octagam 10%, which was approved for dermatomyositis by the US Food and Drug Administration (FDA) in 2021 on the basis of this trial.

Read the Article

If you do not have a NEJM subscription, you may create a free account to view up to two articles per month once on the website. This will then allow review of the entire ProDERM clinical study as published.



Myositis Support and Understanding Association (MSU) is a patient-centered, all-volunteer 501(c)(3) nonprofit organization Empowering the Myositis Community. Founded by Myositis patients, for Myositis patients, MSU provides education, support, advocacy, access to research and clinical trial matching, and need-based financial assistance.

View more information: Myositis Support


Leave a reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2024 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.

Log in with your credentials


Forgot your details?

Register for Free Membership

Send this to a friend